Bayan
01-16-2023, 12:33 AM
It’s been almost a year since the World Health Organization declared the coronavirus outbreak a pandemic.
And the virus is persisting: A downward trend in the U.S. caseload has stalled, and concern about the impact of variants is growing. Yet inoculations are on the rise, and the F.D.A. has approved Johnson & Johnson’s single-dose vaccine, the third to be approved in the U.S.
Today, we check in on the latest about the coronavirus.
Guest: Carl Zimmer (https://www.nytimes.com/by/carl-zimmer?smid=pc-thedaily), a science writer and author of the “Matter” column for The New York Times.
Sign up here (https://www.nytimes.com/newsletters/signup/NTTD?smid=pc-thedaily) to get The Daily in your inbox each morning. And for an exclusive look at how the biggest stories on our show come together, subscribe to our newsletter (https://www.nytimes.com/newsletters/the-daily?module=inline).
Background reading:
After the Johnson & Johnson vaccine approval, President Biden vowed that there would be enough vaccine doses for “every adult in America” (https://www.nytimes.com/2021/03/02/us/politics/merck-johnson-johnson-vaccine.html?smid=pc-thedaily) by the end of May.
For more information about the emerging mutations, check out The Times’s variant tracker. (https://www.nytimes.com/interactive/2021/health/coronavirus-variant-tracker.html?searchResultPosition=5?smid=pc-thedaily)
For more information on today’s episode, visit nytimes.com/thedaily. (http://nytimes.com/thedaily?smid=pc-thedaily)
Transcripts of each episode will be made available by the next workday.
ÃßËÑ... (https://www.nytimes.com/the-daily)
And the virus is persisting: A downward trend in the U.S. caseload has stalled, and concern about the impact of variants is growing. Yet inoculations are on the rise, and the F.D.A. has approved Johnson & Johnson’s single-dose vaccine, the third to be approved in the U.S.
Today, we check in on the latest about the coronavirus.
Guest: Carl Zimmer (https://www.nytimes.com/by/carl-zimmer?smid=pc-thedaily), a science writer and author of the “Matter” column for The New York Times.
Sign up here (https://www.nytimes.com/newsletters/signup/NTTD?smid=pc-thedaily) to get The Daily in your inbox each morning. And for an exclusive look at how the biggest stories on our show come together, subscribe to our newsletter (https://www.nytimes.com/newsletters/the-daily?module=inline).
Background reading:
After the Johnson & Johnson vaccine approval, President Biden vowed that there would be enough vaccine doses for “every adult in America” (https://www.nytimes.com/2021/03/02/us/politics/merck-johnson-johnson-vaccine.html?smid=pc-thedaily) by the end of May.
For more information about the emerging mutations, check out The Times’s variant tracker. (https://www.nytimes.com/interactive/2021/health/coronavirus-variant-tracker.html?searchResultPosition=5?smid=pc-thedaily)
For more information on today’s episode, visit nytimes.com/thedaily. (http://nytimes.com/thedaily?smid=pc-thedaily)
Transcripts of each episode will be made available by the next workday.
ÃßËÑ... (https://www.nytimes.com/the-daily)